Why Medicaid enrollment swelled during the pandemic To view this email as a web page,
click here | | Webinar: Signaling Pathway CDx for Therapy Response Prediction Wednesday, May 26, 2021 | 11am ET / 8am PT Learn how Philips and Qiagen are using mRNA technology in OncoSignal tests to quantify functional activity of disease-relevant signal transduction pathways in any cell and tissue type. This webinar will explore applications for both preclinical disease modeling and clinical measurement of response to targeted therapies and immunotherapies. Register Now. |
Moderna pulled in $1.7B with its COVID-19 vaccine rollout, but it's just getting started Merck takes $170M charge on abandoned COVID-19 drug Medicaid enrollment increased by 5M during pandemic—but not for reasons you may think Biden admin backs proposal to suspend intellectual property on COVID-19 vaccines, angering industry Moderna CEO says he's not losing any sleep over Biden's support for COVID-19 vaccine waiver Novavax shares in the red after vaccine sees 51% efficacy against South African COVID variant COVID-19 tracker: Moderna vaccine appears highly effective in adolescents; Germany rejects U.S.-backed patent waiver UPDATED Coronavirus tracker: 940K have signed up on Healthcare.gov during SEP Featured Story | By Noah Higgins-Dunn Moderna posted sales of $1.94 billion in the first quarter mostly thanks to its COVID-19 vaccine, which generated $1.73 billion in sales during the period. Based on its latest supply agreements, Moderna also boosted its expected 2021 COVID-19 vaccine sales to $19.2 billion. read more |
| |
|---|
|
Top Stories By Nick Paul Taylor Merck has recorded a $170 million charge related to the discontinuation of the COVID-19 candidate it acquired in the takeover of OncoImmune. The action means Merck has taken hundreds of millions of dollars in charges on failed COVID-19 bets in recent months. read more By Robert King Medicaid enrollment swelled by 5 million from March through September 2020 as policy changes could be big drivers in the boost. read more By Eric Sagonowsky Bucking the pharma industry on the closely watched issue of patent rights for COVID-19 vaccines, the Biden administration came out in favor of a proposal at the World Trade Organization to suspend intellectual property protections for pandemic shots. read more By Noah Higgins-Dunn Moderna CEO Stéphane Bancel said he's not concerned about the Biden administration's endorsement of a measure that would temporarily waive intellectual property rights for pandemic vaccines, arguing any new mRNA newcomer would need to invest heavily in ramping up its supply chain. read more By Ben Adams While the world (and the biotech’s investors) wait for full data and possible filing for emergency use of Novavax’s NVX-CoV2373, it has dropped more data on how its shot works against a particular variant. read more By Noah Higgins-Dunn,Kevin Dunleavy,Fraiser Kansteiner Moderna said a trial studying its vaccine in adolescents aged 12 to 17 found the shot to be 96% effective against COVID-19. Germany rejected the Biden administration’s decision to back a controversial intellectual property waiver for pandemic shots. Meanwhile, Moderna's CEO said he's not concerned about the president's endorsement. And more headlines. read more By Healthcare Staff Follow along with the latest COVID-19 news straight from the Fierce Healthcare team. read more |
|
